Innate Pharma SA

FY: Dec 31 2025

FY: Dec 31 2024

FY: Dec 31 2023

FY: Dec 31 2022

FY: Dec 31 2022

FY: Dec 31 2021

FY: Dec 31 2020

FY: Dec 31 2019

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers

Prospectus Supplement with Pricing Information

Free Writing Prospectus

Free Writing Prospectus

Certification of approval for listing and registration on a national securities exchange

Notice of Effectiveness

Notice of Effectiveness

Registration of Securities on Exchange

Registration statement under the Securities Act of 1933 for depositary shares evidenced by American depositary receipts (amendment)

Registration statement for securities of certain foreign private issuers (amendment)

Registration statement under the Securities Act of 1933 for depositary shares evidenced by American depositary receipts

Registration statement for securities of certain foreign private issuers

NOVO NORDISK A S

NOVO NORDISK A S

NOVO NORDISK A S

ASTRAZENECA PLC

NOVO NORDISK A S

NOVO NORDISK A S

Bpifrance Participations SA

Sanofi

Sanofi

none

none

Bpifrance Participations SA

none

none

none

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Post-effective amendment filed solely to add exhibits

Correspondence with the SEC

Correspondence with the SEC

No description available

No description available

No description available

Draft registration statement (confidential submission) (amendment)

Letter from the SEC

No description available

Draft registration statement (confidential submission) (amendment)

Letter from the SEC

Draft registration statement (confidential submission)